Clinical Evidence

Intravaginal culture: 35+ years of evidence.

Intravaginal culture (IVC) is an established clinical technique with decades of published safety and efficacy data. EVEA™ is built on this foundation — engineering a deployable, standardised platform around a proven method.

The underlying method is established. The EVEA™ platform is new.
Intravaginal culture has more than three decades of published clinical literature. EVEA™ builds on this established method through a standardized, engineered device and deployment platform. EVEA™ itself remains investigational and requires its own validation.
Published Literature Base
Intravaginal culture: 35+ years of established evidence.
IVC is not a novel technique. First described in 1988, the method has over three decades of peer-reviewed literature documenting safety, clinical efficacy, and outcomes across multiple countries and fertility centres. EVEA™ is engineered as a standardised, deployable platform built on this established foundation.
Outcome Metric IVC Literature Range Clinical Relevance
Fertilization rate 45–75% Equivalent to conventional IVF; no statistically significant difference.
Cleavage rate 50–80% Early embryo development proceeds normally in-vivo; quality of development is non-inferior to laboratory culture.
Blastocyst formation 30–60% Blastocyst-stage transfer is viable from IVC cycles; morphology and ploidy comparable to conventional IVF.
Clinical pregnancy rate 35–55% per cycle Pregnancy and live-birth outcomes comparable to conventional IVF in good-prognosis cohorts.
Adverse events Rare; primarily mild infection Safety profile is excellent; no embryonic or maternal abnormalities attributable to IVC method reported in literature.

Based on published intravaginal-culture literature. Full reference list available on request.

No full IVF lab. Lower infrastructure.
In appropriately selected patients, predicate IVC literature reports outcomes comparable to conventional IVF, while removing the embryology cleanroom, incubator banks, and HEPA filtration requirement. Launch advanced fertility services without building a $500K–$1M+ lab. Reduce embryologist-hours by ~59% per cycle (Eve operational model, not clinical-trial data).
Eve's approach

Standardised, evidence-backed, deployable.

Eve's strategy is not to prove IVC works — the literature already does that — but to create a standardised, engineered, manufacturable platform that lets hospitals deploy and replicate it. The clinical evidence is established; the innovation is in operational standardisation and regulatory pathway optimisation.

Evidence base

35+ years published

IVC is an established technique with extensive safety and efficacy literature. Eve builds on that foundation, not from scratch.

Device engineering

EVEA™ platform

Single-use, manufacturable device with standardised loading and assessment protocols — engineered for reliable clinical deployment.

Regulatory pathway

Malaysia predicate route

Clear regulatory entry point via Malaysia MDA Class B pathway; freedom-to-operate confirmed; Hong Kong patent filed.

Request clinical data

Full evidence package available for clinical and regulatory partners.

Detailed clinical data, literature references, and deployment-readiness documentation.

Request a briefing →